Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

KK. Ray, M. Ditmarsch, D. Kallend, EJ. Niesor, G. Suchankova, R. Upmanyu, J. Anzures-Cabrera, V. Lehnert, M. Pauly-Evers, I. Holme, J. Štásek, MW. van Hessen, P. Jones, . ,

. 2014 ; 35 (27) : 1792-800.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15023534

AIMS: The effects of cholesteryl ester transfer protein (CETP) inhibition on lipids, inflammation, and markers of high-density lipoprotein (HDL) function, following an acute coronary syndrome (ACS), are unknown. METHODS AND RESULTS: The dal-ACUTE study randomized 300 patients (1 : 1) to dalcetrapib 600 mg/day or placebo within 1 week of an ACS. The primary endpoint was per cent change in HDL-cholesterol (HDL-C) after 4 weeks. Secondary endpoints included apolipoprotein levels, markers of HDL function, and inflammation. Dalcetrapib treatment increased HDL-C and apolipoprotein A1 by 33.7 and 11.8%, respectively (both P < 0.001) and total cholesterol efflux by 9.5% (P = 0.003) after 4 weeks, principally via an increase in non-ATP-binding cassette transporter (ABC) A1-mediated efflux, without statistically significant changes in pre-β1-HDL levels. The increase in total efflux with dalcetrapib correlated most strongly with increases in apolipoprotein A1 and HDL-C (r = 0.46 and 0.43, respectively) rather than the increase in pre-β1-HDL (r = 0.32). Baseline and on-treatment ABCA1-mediated efflux correlated most strongly with pre-β1-HDL levels; in contrast, non-ABCA1-mediated efflux correlated better with apolipoprotein A1 and HDL-C levels. CONCLUSIONS: High-density lipoprotein raised through CETP inhibition with dalcetrapib improves cholesterol efflux, principally via a non-ABCA1-mediated pathway. While HDL-C was increased by one-third, apolipoprotein A1 and total efflux were increased only by one-tenth, supporting the concept of dissociation between improvements in HDL function and HDL-C levels, which may be of relevance to ongoing trials and the development of therapeutic interventions targeting HDL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023534
003      
CZ-PrNML
005      
20150729121751.0
007      
ta
008      
150709s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/eurheartj/ehu105 $2 doi
035    __
$a (PubMed)24639426
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ray, Kausik K $u Cardiovascular Sciences Research Centre, St George's University of London, Cranmer Terrace, London, SW17 ORE UK kray@sgul.ac.uk.
245    14
$a The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial / $c KK. Ray, M. Ditmarsch, D. Kallend, EJ. Niesor, G. Suchankova, R. Upmanyu, J. Anzures-Cabrera, V. Lehnert, M. Pauly-Evers, I. Holme, J. Štásek, MW. van Hessen, P. Jones, . ,
520    9_
$a AIMS: The effects of cholesteryl ester transfer protein (CETP) inhibition on lipids, inflammation, and markers of high-density lipoprotein (HDL) function, following an acute coronary syndrome (ACS), are unknown. METHODS AND RESULTS: The dal-ACUTE study randomized 300 patients (1 : 1) to dalcetrapib 600 mg/day or placebo within 1 week of an ACS. The primary endpoint was per cent change in HDL-cholesterol (HDL-C) after 4 weeks. Secondary endpoints included apolipoprotein levels, markers of HDL function, and inflammation. Dalcetrapib treatment increased HDL-C and apolipoprotein A1 by 33.7 and 11.8%, respectively (both P < 0.001) and total cholesterol efflux by 9.5% (P = 0.003) after 4 weeks, principally via an increase in non-ATP-binding cassette transporter (ABC) A1-mediated efflux, without statistically significant changes in pre-β1-HDL levels. The increase in total efflux with dalcetrapib correlated most strongly with increases in apolipoprotein A1 and HDL-C (r = 0.46 and 0.43, respectively) rather than the increase in pre-β1-HDL (r = 0.32). Baseline and on-treatment ABCA1-mediated efflux correlated most strongly with pre-β1-HDL levels; in contrast, non-ABCA1-mediated efflux correlated better with apolipoprotein A1 and HDL-C levels. CONCLUSIONS: High-density lipoprotein raised through CETP inhibition with dalcetrapib improves cholesterol efflux, principally via a non-ABCA1-mediated pathway. While HDL-C was increased by one-third, apolipoprotein A1 and total efflux were increased only by one-tenth, supporting the concept of dissociation between improvements in HDL function and HDL-C levels, which may be of relevance to ongoing trials and the development of therapeutic interventions targeting HDL.
650    _2
$a ABCA1 protein $x metabolismus $7 D064286
650    _2
$a akutní koronární syndrom $x farmakoterapie $7 D054058
650    _2
$a nestabilní angina pectoris $x farmakoterapie $7 D000789
650    _2
$a anticholesteremika $x aplikace a dávkování $7 D000924
650    _2
$a apolipoproteiny $x metabolismus $7 D001053
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a C-reaktivní protein $x metabolismus $7 D002097
650    _2
$a transportní proteiny pro estery cholesterolu $x antagonisté a inhibitory $7 D053480
650    _2
$a HDL-cholesterol $x metabolismus $7 D008076
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a metabolismus lipidů $x účinky léků $7 D050356
650    _2
$a lipoproteiny $x metabolismus $7 D008074
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a infarkt myokardu $x farmakoterapie $7 D009203
650    _2
$a sulfhydrylové sloučeniny $x aplikace a dávkování $7 D013438
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ditmarsch, Marc $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Kallend, David $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Niesor, Eric J $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Suchankova, Gabriela $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Upmanyu, Ruchi $u Roche Products Ltd, Welwyn Garden City, UK.
700    1_
$a Anzures-Cabrera, Judith $u Roche Products Ltd, Welwyn Garden City, UK. $7 gn_A_00007665
700    1_
$a Lehnert, Valerie $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Pauly-Evers, Meike $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Holme, Ingar $u Department of Endocrinology, Obesity and Preventive Medicine, Oslo University Hospital, Ulleval, Oslo, Norway.
700    1_
$a Štásek, Josef $u Charles University Faculty Hospital, Hradec Králové, Czech Republic.
700    1_
$a van Hessen, Maarten W J $u Groene Hart Ziekenhuis, Gouda, The Netherlands.
700    1_
$a Jones, Peter $u Baylor College of Medicine, Houston, TX, USA.
700    1_
$a ,
773    0_
$w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 35, č. 27 (2014), s. 1792-800
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24639426 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150729121837 $b ABA008
999    __
$a ok $b bmc $g 1083871 $s 906527
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 35 $c 27 $d 1792-800 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
LZP    __
$a Pubmed-20150709
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace